Opening soon—Ages 8 Years to 70 Years

Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study

Sponsor: Peking University People's Hospital · NCT06776198 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

OsteosarcomaTranscriptomeTumor MicroenvironmentPrecision Medicine

What it tests

Chemotherapydrug

Where it's running0 sites

No sites are listed on ClinicalTrials.gov yet. Check the official record for updates.

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* (i) patients who have been suspected for osteosarcoma with enough clinical or radiographic information;
* (ii) patients who have evaluable lesions to resect or follow;
* (iii) patients who are planned to be operate with enough flesh specimens for this study.

Exclusion Criteria:

* (i) clinical information was not complete;
* (ii) lost to follow-up.

Updated 2025-01-24 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.